Comparison
Alpha-Lipoic Acid vs Citicoline
Side-by-side of Alpha-Lipoic Acid and Citicoline. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Alpha-Lipoic Acid
Alpha lipoic acid supplement guide: 600 mg/day oral dosing, R-ALA vs racemic absorption, neuropathy trial data, antioxidant mechanism, interactions.
Citicoline
Citicoline supplement profile: CDP-choline as a phosphatidylcholine precursor, Cognizin dosing 250-2000 mg, cognition trials, stroke recovery evidence.
Effects at a glance
Alpha-Lipoic Acid
- •Approved Rx for diabetic neuropathy in Germany at 600 mg/day IV (Thioctacid) since 1960s
- •Improves neuropathy symptoms (TSS, NIS) at 600 mg/day IV across ALADIN and SYDNEY trials
- •R-ALA enantiomer absorbs 40-100% better than racemic mixtures
- •Activates AMPK; produces small HbA1c reductions in T2DM
- •Plasma half-life ~30 minutes; split dosing or sustained-release is standard
- •Hypoglycemia risk with insulin or sulfonylureas; medication adjustment may be required
Citicoline
- •Choline donor and phosphatidylcholine precursor; oral bioavailability roughly 99%
- •Standard prescription medication for stroke recovery and vascular cognitive impairment in much of the world
- •Healthy-adult cognitive trials (Cognizin) report small gains in attention and working memory at 250 to 500 mg/day
- •ICTUS trial (n=2,298) was negative on stroke recovery in the modern thrombolysis era
- •Lower per-gram choline content than alpha-GPC (~18% vs ~40%), meaning smaller TMAO load at equivalent dose
- •Long uridine half-life (~56 hours) supports once or twice daily dosing
Side-by-side
| Attribute | Alpha-Lipoic Acid | Citicoline |
|---|---|---|
| Category | supplement | supplement |
| Also known as | ALA, thioctic acid, R-ALA, R-lipoic acid | CDP-choline, cytidine 5'-diphosphocholine, Cognizin |
| Half-life (hr) ↗ | 0.5 | 56 |
| Typical dose (mg) ↗ | 600 | 500 |
| Dosing frequency | 1 to 3 times daily on empty stomach | 1 to 2 times daily |
| Routes | oral, iv | oral, intravenous |
| Onset (hr) | 0.5 | 1 |
| Peak (hr) | 1 | 2 |
| Molecular weight | 206.33 | 488.32 |
| Molecular formula | C8H14O2S2 | C14H26N4O11P2 |
| Mechanism | Dual lipid- and water-soluble antioxidant; redox cycles with dihydrolipoic acid (DHLA) to scavenge ROS, regenerate vitamin E and C, and chelate transition metals. Activates AMPK in liver and muscle; cofactor for pyruvate and alpha-ketoglutarate dehydrogenase complexes. | Hydrolyzed to cytidine and choline after absorption; both cross the blood-brain barrier and are recombined intracellularly to reform CDP-choline, supporting phosphatidylcholine synthesis and acetylcholine production. |
| Legal status | Dietary supplement (US, UK, Canada, most EU); prescription drug for diabetic neuropathy in Germany | Dietary supplement (US, Cognizin GRAS); prescription medication in most of the world |
| WADA status | allowed | allowed |
| DEA / Rx | Not scheduled | OTC supplement (US); Rx in most of the world |
| Pregnancy | Insufficient data; precautionary avoidance | Insufficient data for routine use |
| CAS | 62-46-4 | 987-78-0 |
| PubChem CID | 864 | 13804 |
| Wikidata | Q161227 | Q411470 |
Safety profile
Alpha-Lipoic Acid
Common side effects
- nausea
- abdominal discomfort
- diarrhea
- sulfurous odor
- rash (rare)
Contraindications
- pregnancy and lactation (insufficient safety data)
- active insulin autoimmune syndrome predisposition
Interactions
- insulin and sulfonylureas: additive hypoglycemia; medication dose adjustment may be required(major)
- thyroid hormone: may reduce T4 to T3 conversion at high doses(moderate)
- biotin: ALA competes with biotin uptake; chronic use can induce biotin insufficiency(minor)
- iron supplements: ALA chelates iron and reduces absorption; separate dosing(moderate)
- chemotherapy (oxidative-stress-dependent agents): theoretical interference; coordinate with oncology team(moderate)
Citicoline
Common side effects
- mild GI upset
- headache
- restlessness
- occasional insomnia with evening dosing
Contraindications
- concurrent strong anticholinergic therapy
- established cardiovascular disease (TMAO concern, smaller than alpha-GPC)
Interactions
- anticholinergic medications: partial mutual antagonism(minor)
- cholinesterase inhibitors: additive cholinergic effect(minor)
- antimetabolite chemotherapy (5-FU): theoretical cytidine pathway interaction(minor)
Which Should You Take?
Alpha-Lipoic Acid and Citicoline score evenly on the criteria we weight (goal breadth, legal accessibility, evidence depth). The conditionals below should drive the decision more than any aggregate score.
- → If your priority is metabolic health and glucose control, pick Alpha-Lipoic Acid.
- → If your priority is healthspan extension, pick Alpha-Lipoic Acid.
- → If your priority is focus or working memory, pick Citicoline.
- → If your priority is stroke recovery, pick Citicoline.
Edge case: Half-lives differ materially (Alpha-Lipoic Acid ~0.5 hr vs Citicoline ~56 hr). Citicoline reaches steady state faster; Alpha-Lipoic Acid is easier to dial in if tolerability is uncertain.
Default choice: either is defensible. Alpha-Lipoic Acid edges out on goal breadth + legal accessibility; Citicoline is the right call if your priority sits in the goals listed above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Alpha-Lipoic Acid and Citicoline?
Alpha-Lipoic Acid and Citicoline differ in category (supplement vs supplement), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Alpha-Lipoic Acid or Citicoline?
Alpha-Lipoic Acid half-life is 0.5 hours; Citicoline half-life is 56 hours.
Can you stack Alpha-Lipoic Acid with Citicoline?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper